New study checks how liver disease affects drug processing
NCT ID NCT06825559
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This early-stage study looks at how the drug saroglitazar is handled by the body in people with moderate liver damage from cholestatic liver disease. Six adults with cirrhosis will take the drug every other day, and researchers will measure drug levels and watch for side effects. The goal is to gather safety and dosing information, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTATIC LIVER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zydus Site US001
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.